Clinical significance of MYC expression and/or "High-grade" morphology in non-burkitt, diffuse aggressive B-cell lymphomas: A SWOG s9704 correlative study

American Journal of Surgical Pathology

Volumn 38, Issue 4, 2014, Pages 494-501

  Cook, James R ^a   Goldman, Bryan ^b   Tubbs, Raymond R ^a   Rimsza, Lisa ^c   Leblanc, Michael ^b   Stiff, Patrick ^d   Fisher, Richard ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cell lymphoma unclassifiable with features intermediate between DLBCL and BL; Diffuse large B cell lymphoma; Immunohistochemistry; MYC

Indexed keywords

ANTINEOPLASTIC AGENT; MYC PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BIOSYNTHESIS; CANCER GRADING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TISSUE MICROARRAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; TISSUE ARRAY ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896655386     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000147     Document Type: Article

References (43)

1. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49: 2112-2135.
2. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
3. Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood. 2001;97: 3713-3720.
4. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
5. Jaffe ES, Harris NL, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
6. Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: A review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program. 2011;2011:506-514.
7. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29:1652-1660.
8. Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29:1835-1843.
9. Thomas DA, O'Brien S, Faderl S, et al. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: Should these be treated as different diseases? Curr Hematol Malig Rep. 2011;6:58-66.
10. Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:265-266.
11. Kanagal-Shamanna R, Medeiros LJ, Lu G, et al. High-grade B cell lymphoma, unclassifiable, with blastoid features: An unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology. 2012;61:945-954.
12. Li S, Lin P, Young KH, et al. MYC/BCL2 double-hit high-grade Bcell lymphoma. Adv Anat Pathol. 2013;20:315-326.
13. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood. 2009;114:2273-2279.
14. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34:327-340.
15. Tomita N. BCL2, MYC dual-hit lymphoma/leukemia. J Clin Exp Hematop. 2011;51:7-12.
16. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935-943.
17. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460-3467.
18. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21:1156-1167.
19. Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. Plos One. 2012;7:e33813.
20. Green TM, Nielsen O, de Stricker K, et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012;36:612-619.
21. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in R-CHOP treated diffuse large B-cell lymphoma. J Clin Oncol. 2012;30:3452-3459.
22. Stiff PJ, Unger JM, Cook JR, et al. Randomized phase III U.S./ Canadian intergroup trial (SWOG S9704) comparing CHOP±R for six cycles followed by autotransplant for patients with highintermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol. 2011;29:8001. [Abstract].
23. Stiff PJ, Unger J, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin lymphoma. N Engl J Med. 2013;369:1681-1690.
24. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275-282.
25. Ly B, Cotta CV. Utility of automated immunohistochemical stain for MYC in the identification of B-cell lymphoproliferative disorders with MYC translocation. Mod Pathol. 2012;25:354a.
26. Wongchaowart NT, Kim B, Hsi ED, et al. t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomas. J Cutan Pathol. 2006;33:286-292.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
28. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
29. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B. 1972;34:187-220.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Haralambieva E, Boerma EJ, van Imhoff GW, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol. 2005; 29:1086-1094.
32. Linch DC. Burkitt lymphoma in adults. Br J Haematol. 2012;156: 693-703.
33. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet. 2012;379:1234-1244.
34. Leonici L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:262-264.
35. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
36. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442.
37. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
38. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood. 2011;117:5019-5032.
39. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15: 5494-5502.
40. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large Bcell lymphoma treated with rituximab. J Clin Oncol. 2011;29:200-207.
41. Tapia G, Lopez R, Munoz-Marmol AM, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology. 2011;59:672-678.
42. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253-2263.
43. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates highrisk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121: 4021-4031.